

Pierre Saintigny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6267226/publications.pdf>

Version: 2024-02-01

15
papers

1,063
citations

1039406

9
h-index

1125271

13
g-index

18
all docs

18
docs citations

18
times ranked

2505
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 11-29.	1.5	15
2	MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. , 2022, 10, e003917.		19
3	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
4	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 106-122.	1.3	12
5	PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achillesâ€™ heel?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101553.	0.7	11
6	Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in invasiveness of head and neck cancers. <i>Translational Oncology</i> , 2021, 14, 100878.	1.7	0
7	Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 439-451.	0.5	34
8	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 614332.	1.3	33
9	OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 256-265.	1.0	18
10	Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. <i>Oral Oncology</i> , 2021, 119, 105368.	0.8	15
11	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020, 9, 1828.	1.8	13
12	Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. <i>Trends in Cancer</i> , 2019, 5, 365-390.	3.8	11
13	Circulating tumor DNA profiling of lung cancer patients treated with EGFR inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23060-e23060.	0.8	2
14	An Epithelialâ€™Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	3.2	848
15	Data sharing in the era of precision medicine: a scientometric analysis. <i>Precision Cancer Medicine</i> , 0, 2, 30-30.	1.8	2